Lymphoma Clinical Trials in Zhengzhou
13 recruitingZhengzhou, China
Showing 1–13 of 13 trials
Recruiting
Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Untreated Follicular Lymphoma
AstraZeneca1,018 enrolled135 locationsNCT06549595
Recruiting
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Hoffmann-La Roche300 enrolled12 locationsNCT07200375
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled75 locationsNCT06084936
Recruiting
Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
B-cell Non Hodgkin LymphomaFollicular Lymphoma ( FL)Large B-Cell Lymphoma (LBCL)
AstraZeneca240 enrolled94 locationsNCT06526793
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca276 enrolled63 locationsNCT06564038
Recruiting
Phase 1Phase 2
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.112 enrolled15 locationsNCT05800977
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502
Recruiting
Phase 1Phase 2
DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
Diffuse Large B Cell Lymphoma
Dizal Pharmaceuticals150 enrolled16 locationsNCT07059650
Recruiting
Phase 1Phase 2
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Large B-cell Lymphoma
Genfleet Therapeutics (Shanghai) Inc.51 enrolled2 locationsNCT06375733
Recruiting
Phase 2
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL)
Xynomic Pharmaceuticals, Inc.170 enrolled23 locationsNCT03936153
Recruiting
Phase 1
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-Cell Non Hodgkin Lymphoma
Peking University Cancer Hospital & Institute42 enrolled3 locationsNCT06313957
Recruiting
Phase 3
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Mantle Cell Lymphoma
InnoCare Pharma Inc.476 enrolled39 locationsNCT06363994
Recruiting
Not Applicable
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
Primary Ocular Adnexal MALT Lymphoma
Zhongshan Ophthalmic Center, Sun Yat-sen University108 enrolled2 locationsNCT06190301